Elevance Health Inc. (ELV) has been a topic of significant interest among various investment and asset management firms, with continuous fluctuations in stock holdings being reported. Some firms have reduced their positions in Elevance Health, like Choreo LLC, Ninety-One UK, and Sumitomo Mitsui Trust Group, while others, such as Generate Investment Management and Iridian Asset Management, have increased their shares. The company's Q4 sales were in line with estimates, and despite a decline in Medicaid membership, their Q4 revenue hit $45B. Furthermore, Elevance Health's shares were sold by various investment firms but increased purchases were reported by Lawson Kroeker Investment, Robeco Institutional, and Forsta AP Fonden. High medical costs have caused the company to cut its profit forecast, but robust growth is anticipated for 2025, and the firm is seen as an undervalued healthcare juggernaut. Despite a reported 50% plunge in profit, the shares jumped by 2.2% on news of a dividend hike. Elevance has faced Medicaid challenges but has reported strong Q3 results and is viewed bullishly by hedge funds.
Elevance Health ELV News Analytics from Wed, 25 Sep 2024 07:00:00 GMT to Sat, 08 Feb 2025 21:38:34 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor -5
